Citi initiated coverage of Cullinan Therapeutics (CGEM) with a Buy rating and $33 price target The firm says the company is advancing a pipeline of T-cell engagers across autoimmune and oncology settings. Cullinan is entering a “catalyst-rich” 2026, the analyst tells investors in a research note. Citi sees a favorable risk/reward into the upcoming CLN-978 readouts.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CGEM:
- Cullinan Oncology: Undervalued Autoimmune Pipeline With 2026 CLN-978 Catalysts and Additional Oncology Upside Supporting Buy Rating
- TheStreet Pro Analysts Say, “Big Tech Names are Anything But Cheap – Buy These 2 Stocks Instead”
- Cullinan Therapeutics initiated with a Buy at Guggenheim
- Cullinan: Buy Rating Reiterated on 2026 Clinical Catalysts and Undervalued Pipeline Upside
- Cullinan Therapeutics price target raised to $27 from $26 at H.C. Wainwright